Investor Relations

We are committed to transparent communication, sound governance, and long-term value creation — keeping our investors informed and confident.

Investment Highlights

A track record built on three decades of industry experience, consistent performance, and steady growth in the cross-border pharmaceutical supply chain.

0

Years in Operation

Established in 1995 with nearly 30 years of cross-border logistics expertise

0

Pharmaceutical Licences

Covering OTC, prescription drugs, dangerous drugs, and antibiotics in Hong Kong

0

Sq. Ft. HK Warehouse

Temperature-controlled facilities in Hong Kong for pharmaceutical storage

0

Tons Monthly Shipment

Monthly shipment volume exceeds 100 tons with 10-ton daily cargo capacity

Financial Overview

Our financial stability is built on long-term client relationships, operational efficiency, and a growing presence in global pharmaceutical and healthcare trade.

Revenue Summary (HK$)

Period Revenue Growth
FY 2025 1,386,211 23.85
FY 2024 1,820,362 26.15%
FY 2023 2,464,925 8.50%
FY 2022 2,271,827 42.75%
FY 2021 1,591,494 58.01%
FY 2020 3,789,881 22.83%
FY 2019 4,911,301 0.97%
FY 2018 4,959,402 0.93%

Revenue Trend

2018
2019
2020
2021
2022
2023
2024
2025
KEY METRICFY 2025
Gross Margin (HK$) -0.72%
Net Profit Margin (HK$) -0.74%
TSE (HK$) 81,023